Clinical trial
Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Subjects With High Risk Smoldering Multiple Myeloma (SMM)
NCT03289299 is registered in ClinicalTrials.gov with International Myeloma Foundation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Subjects With High Risk Smoldering Multiple Myeloma (SMM)
- Lead sponsor
- International Myeloma Foundation
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- May 25, 2018
- Completion date
- November 15, 2031
- Enrollment
- 87 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.